STUDresearch · Peptide
Gonadorelin
Also known as
GnRH · Gonadotropin-releasing hormone · LHRH · Luteinizing hormone-releasing hormone · Gonadorelin acetate · Gonadorelin hydrochloride · Factrel (clinical brand discussion; US product historically discontinued for commercial reasons) · Lutrepulse / Lutrelef-class discussion · pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 · Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Some talk
Systemic
SubQ / IV
Reproductive & endocrine peptides
Systemic: synthetic native-sequence decapeptide GnRH hits pituitary GnRH receptors → LH + FSH → gonads.
What people say
Gonadorelin is synthetic native-sequence GnRH. A pulse can trigger pituitary LH and FSH, whereas sustained exposure can desensitize that signaling; it is not hCG or a depot GnRH agonist.
Doses people talk about
Actual self-report amounts lead. Frequency-only or concentrationless syringe-unit posts stay in context rather than being promoted to dose rows.
How it may feel
Acute bolus effects are often minimal but can include flushing, headache, nausea or lightheadedness. TRT-adjunct accounts conflict: some report no felt effect or preserved size, others shrinkage, low libido, rash, testicular pain, hot flashes or cognitive fog.
Inspected adverse TRT-adjunct account200 mcg once weekly
Used with 140 mg testosterone; the author reported rash, hot flashes, testicular pain, lightheadedness and cognitive fog, alongside some fullness and harder erections, then stopped. Co-use prevents clean attribution.
Community clinic band50–100 mcg per administration
Commonly described two or three times weekly in clinic/forum TRT-adjunct culture; not equivalent to physiologic pulsatile delivery.
Diagnostic challenge~100 mcg once in adults
Historical labeled diagnostic SC or IV challenge context, not a lifestyle cycle or TRT-maintenance dose.
Clinical pulsatile pump~5 mcg per pulse, historical range ~1–20 mcg
Specialist SC or IV administration about every 90 minutes for selected hypogonadotropic infertility contexts; not a DIY translation.
Higher repeated research exposure~200–400 mcg/day
Older repeated-exposure work associated higher continuous-style exposure with early LH/FSH rise followed by fading response; more exposure is not necessarily more stimulation.
Half-life & effect duration
- Half-life in the body
- IV / under-the-skin injection · initial phaseAbout 2–10 minutes
- Same routes · terminal phaseAbout 10–40 minutes
- Felt duration people report
- Positive / neutral accountsFullness or erection changes, preserved size, or no felt effect
- Other accountsLow libido, shrinkage or adverse effects during repeated use
Cycles people discuss
A diagnostic single dose, q90-minute fertility pump, intermittent TRT-adjunct use and continuous exposure are different contexts. Continuous non-pulsatile exposure can produce the opposite endocrine effect through desensitization.
Timing
Clinic/forum TRT-adjunct schedules range from a few injections per week to daily or twice-daily use, with convenience and compliance in the debate. Clinical pump-study samples were often timed about 30 minutes after a pulse; community panels usually were not pulse-timed.
Stacks
TRT is the dominant community co-use and the main confound. hCG is a comparison or substitute, not a dose-equivalent; SERMs and fertility gonadotropins change the endocrine context again.
Watch for
Desensitization paradox: Too frequent, continuous, or chronically high exposure can suppress LH/FSH after an initial rise — opposite of the TRT-adjunct goal.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
The reviewed monograph reports minutes-scale initial and terminal gonadorelin half-lives after IV or SC administration.
Lutrepulse pharmacokinetics reports initial 2–10 minutes and terminal 10–40 minutes in healthy and hypogonadotropic humans, with kidney metabolism/clearance and prolonged exposure in renal failure.
Broad phase-specific ranges from an older product monograph; not validated for compounded troches, nasal products, gray-market vials or every renal state.
- Lutrepulse gonadorelin acetate product monograph (opens in a new tab)PDF pages 21–22, pharmacokinetics: IV/SC initial half-life 2–10 minutes and terminal half-life 10–40 minutes in healthy and hypogonadotropic subjects; kidney metabolism/clearance and prolongation in renal failure are described.2016 Canadian product monograph for a specific clinical product and pump context; broad ranges and no transfer to compounded sublingual/nasal or gray-market formulations.
Felt duration people report
Community felt effects and testicular outcomes conflict, and they do not track the minutes-scale parent half-life.
A 200 mcg weekly account with testosterone reported multiple adverse effects plus some fullness/erection changes, then stopping. Other users reported no felt effect or preserved size, while some reported shrinkage, low libido or no laboratory stimulation.
TRT and other co-therapy, non-physiologic schedules, uncertain products, concentrationless unit posts, no consistent pulse-timed labs, and no controlled attribution.
- Gonadorelin clinic dose adverse experience (opens in a new tab)Original post and same-author updates: 200 mcg once weekly with 140 mg testosterone; rash, hot flashes, severe testicular pain, lightheadedness and cognitive fog, with some fullness/harder erections; author later stopped TRT and gonadorelin and described an initially difficult week followed by return toward normal.Single co-treated account, no blinded rechallenge, incomplete clinical data and no way to separate gonadorelin, testosterone, expectations or underlying conditions.
- One-year gonadorelin community experience discussion (opens in a new tab)Complete post and visible replies: one participant described about a year of twice-weekly use with no shrinkage and no felt effects; another described shrinkage, high energy and low libido; other responses varied.Different users, doses, products and TRT contexts; no standardized examination, semen analysis, pulse-timed labs or product verification.
- Switching from hCG to gonadorelin — experience thread (opens in a new tab)Original post and visible replies: reports range from no noticeable effect to claimed size preservation without LH/FSH recovery, while others preferred hCG. Concentrationless syringe-unit descriptions were not converted to micrograms.Uncontrolled switches, variable washout, TRT co-use and missing concentration/laboratory details; subjective size is not fertility or pituitary-response proof.
- Lutrepulse gonadorelin acetate product monograph (opens in a new tab)PDF pages 21–22, pharmacokinetics: IV/SC initial half-life 2–10 minutes and terminal half-life 10–40 minutes in healthy and hypogonadotropic subjects; kidney metabolism/clearance and prolongation in renal failure are described.2016 Canadian product monograph for a specific clinical product and pump context; broad ranges and no transfer to compounded sublingual/nasal or gray-market formulations.
What people say
- Dual gonadotropin signal: Unlike pure LH-mimetics (hCG), discussion stresses both LH (Leydig/T / intratesticular T environment) and FSH (spermatogenesis / Sertoli-tubule support). forum
- Testicular volume / fullness on TRT: Some clinics and users report less atrophy or restored fullness vs T-only; many clinicians still rate hCG more reliable and predictable for size and function. forum
- Libido anecdotes: Some feel better desire/“fullness” when labs move; many report no subjective change despite dosing. Community self-report apps sometimes list libido as a logged “benefit,” but confounded and small-n. anecdote
- hCG access driver: Interest spiked when compounded hCG became harder to get or more expensive; gonadorelin filled clinic formulary gaps. forum
- hCG long-run swap lore: Some switch after years of hCG citing LH-receptor desensitization lore and hope gonadorelin restores dual LH+FSH signaling; reverse swaps are common when size/labs disappoint. forum
- LH/FSH rise (if pituitary responds): Single ~100 mcg challenges and intermittent boluses often show LH (sometimes FSH) up on labs when gonadotrophs still work. trial
- AAS-history challenge data: In a mixed cohort (AAS history, healthy men, hypogonadal men), single ~100 mcg GnRH raised LH in all groups (>2× overall); some AAS-history subjects still only reached low-normal LH percentiles vs controls. trial
- Cost / access framing: Clinic pages sometimes position gonadorelin as the cheaper size/fullness option (order-of-magnitude lower monthly cost quotes than hCG in some practices) while reserving hCG when fertility or long-term testicular function is the priority. forum
- Fertility / sperm narratives: Pump literature in hypogonadotropic men shows spermatogenesis induction; TRT-adjunct fertility preservation is less proven than classic hCG ± FSH and is not guaranteed. trial
- Earlier spermatogenesis vs gonadotropins (selected CHH data): Nonrandomized comparative work: pulsatile gonadorelin (~10 mcg SC q90 min via pump) associated with earlier sperm appearance than cyclical hCG/HMG (median ~6 vs ~14 months); overall induction rates high in both arms and not clearly superior on success rate alone. trial
- CHH pump outcomes (broader series): Multi-month portable-pump work reports rises in testicular volume, serum T, and penile length measures over 0.5–2 years; sperm induction efficiency in the ~80% range in some follow-ups, with earlier onset in younger men and those with larger baseline testes. trial
- FHA / ovulation pump context: Subcutaneous pulsatile gonadorelin (example literature ~10 mcg q90 min) discussed with high per-cycle ovulation rates in functional hypothalamic amenorrhea cohorts. trial
- Diagnostic use: Factrel-class single-dose GnRH stim tests are established for HPG axis evaluation. trial
- Axis-restart case reports: Short multi-day courses (e.g. successive ~200 mcg days with 2-hour LH/FSH/T draws) reported to lift LH/FSH/T in selected post-AAS suppression cases with multi-month follow-up in one report — sparse, not a universal PCT template. trial
- Physiologic framing vs hCG: Marketed as “upstream / native pulse / FSH included” vs direct Leydig stimulation; fan camps disagree on real-world TRT superiority. forum
Doses people talk about
- TRT adjunct — common clinic/forum band: ~50–100 mcg subcutaneous 2–3×/week is widely quoted for testicular-maintenance talk. forum
- Low intermittent clinic examples: ~50 mcg once weekly or ~50–100 mcg twice weekly reported when clinics swapped hCG for gonadorelin; some forum posts describe ~0.5 mL twice weekly without always confirming mcg. forum
- Mid band (vendor/education charts): ~100 mcg SC 2–3×/week appears as a typical TRT-adjunct template (e.g. PeptIQ-style summaries). forum
- Every-other-day / 1–3 day spacing clinic talk: Some clinician education content cites ~100 mcg SC every 1–3 days depending on goals; EOD ~100 mcg for multi-week lab-driven blocks also appears in video protocol talk. forum
- Daily / near-daily advocates: ~100–150 mcg daily or every other day, or ~100–200 mcg per injection daily, framed as closer to physiology given the minutes-scale half-life. forum
- Twice-daily talk: Optimization writeups cite ~100–200 mcg SC twice daily to better mimic pulses; compliance is the practical limit. forum
- Provider note examples: Community AMA-style notes have cited ~100 mcg SQ twice daily while on TRT for fertility-maintenance talk — not a consensus standard. forum
- Higher intermittent boluses: ~200 mcg 2–3×/week and ~100–200 mcg (sometimes ~400 mcg in older continuous-style research) show up in PCT/“strong pulse” discussion. forum
- Self-report dose buckets (app/community logs): Anonymized small-n logs show a median/most-common injection bucket around 100–200 mcg with reported spans ~50–400 mcg — not clinical evidence. anecdote
- Sublingual mini-troche (compounded pharmacy menus): Example menu dosing: gonadorelin ~500 mcg mini-troche dissolved sublingually on empty stomach ~3–4×/week — bioavailability vs SC is not well characterized publicly; treat as clinic compounding practice, not trial-matched PK. forum
- Nasal spray (minority / convenience): Research and historical products (e.g. Kryptocur-class LHRH nasal for other indications) exist; community charts sometimes quote ~100 mcg per spray or higher total daily nasal mcg because absorption is lower than injection; TRT-adjunct nasal efficacy evidence is thinner than SC. forum
- Frequency vs physiology debate: Natural GnRH is multi-pulse per day (~q60–120 min); 1–3 clinic shots/week is a convenience/cost compromise, not a true pulse pump — skeptics call sparse schedules underdosing physiology; supporters cite cost/compliance and some LH lab bumps anyway. forum
- Clinical pulsatile pump — female FHA / amenorrhea (Lutrepulse-class): Often ~5 mcg (range ~1–20 mcg) every ~90 minutes SC or IV for selected hypogonadotropic infertility / hypothalamic amenorrhea protocols, with multi-week courses (e.g. ~21-day reassessment windows in product literature). trial
- Clinical pulsatile pump — male CHH research: Starting ~10 mcg SC every 90 min (~16 pulses/24 h) is common; titration often ~3–15 mcg/pulse (sometimes 10–15 mcg start, ±5 mcg steps) to keep LH/FSH roughly mid-physiologic and T in range. trial
- Historical micro-pump fertility cases: Older IV portable-pump work used ~5–20 mcg every ~89 minutes in tertiary hypogonadism with sperm appearance on the order of weeks to a few months in case reports. trial
- Desensitization dose caution (research): Older work with repeated high daily exposure (e.g. ~400 mcg/day alongside androgens over many weeks) linked early LH/FSH rise then fade by ~days 10–14 and further decline; ~200 mcg/day was discussed as a slower decline path — continuous high boluses are not “more is better.” trial
- Framing: Discussed community, clinic, and labeled clinical ranges only — not advice, not prescriptions, not DIY protocols. Units are micrograms (mcg), not hCG IU. forum
- Diagnostic single dose (Factrel-class / Mayo-style labeling discussion): Adults ~100 mcg (0.1 mg) once SC or IV; pediatric weight-based challenges often ~2 mcg/kg, capped near 100 mcg in historical labeling discussion. trial
- PCT / post-suppression research snippets: Single ~100 mcg challenges after AAS exposure; case-level successive daily ~200 mcg × ~3 days with serial hormone draws; some vendor education charts say “~100 mcg once, avoid multi-day continuous” and even “do not exceed one-time ~200 mcg” — that short-challenge framing conflicts with multi-month intermittent TRT clinic practice; note the conflict honestly. trial
How it may feel
- Days 1–7: Focus is injection habit and early labs, not dramatic mood; libido change is inconsistent early. forum
- Weeks 2–4: Common checkpoint for scrotal fullness feel, mid-protocol LH/FSH (± T/E2), and “stay / switch to hCG / add SERM” decisions. forum
- Weeks 4–8: Some stick for fertility markers or ongoing TRT adjunct; weak responders often abandon for hCG or add a SERM rather than endless mcg escalation. forum
- Multi-month TRT adjunct: Ongoing clinic use discussed as continuous co-therapy; public long solo logs that cleanly isolate gonadorelin from T, AI, and lifestyle are thin. forum
- No lab change: High exogenous T/E2 negative feedback, primary testicular failure, or non-responsive pituitary blunt output — reassess mechanism, not only mcg. forum
- First minutes–hours: Usually little acute “feel”; occasional short flush, warmth, headache, nausea, or lightheadedness after bolus (Factrel-class labeling-era systemic effects described as uncommon after ~100 mcg). trial
- Same-day labs logic: Downstream LH/FSH can rise while the peptide is already gone; clinical pulse studies often sample ~30 min after a pulse; challenge protocols may draw at ~2 hours after a bolus in some case reports. trial
- Months (pump/fertility contexts): Clinical hypogonadotropic work tracks spermatogenesis over months (median sperm appearance on the order of ~6 months in one pulsatile-vs-gonadotropin comparison; other series report mean sperm emergence ~6–7 months with earliest around ~3 months). trial
Cycles people discuss
- TRT adjunct: Often continuous multi-month co-therapy with labs guiding stay, titrate, or switch — not a classic “blast cycle.” forum
- PCT / restart narratives: Short multi-day boluses or multi-week intermittent courses, frequently co-mentioned with SERMs; evidence is mostly case/anecdote plus diagnostic-style challenges, not large PCT RCTs. forum
- If flat labs: Users/clinics usually stop or switch to hCG (or add SERM) rather than endless mcg escalation. forum
- hCG washout / swap: Some try gonadorelin after long hCG runs citing LH-receptor desensitization lore; reverse swaps happen when size/labs disappoint. forum
- Vendor short-course framing vs clinic reality: Some research-education charts limit challenge-style use to ~1–3 consecutive days then pause weeks if labs are flat; men’s clinics commonly run months of 2–3×/week co-therapy — these are different use cultures, not one protocol. forum
- Diagnostic: Single-dose stim test — not a lifestyle cycle. trial
- Pump fertility (male CHH / hypogonadotropic): Weeks to many months under specialist care; dose adjusted by LH/FSH/T and clinical response; spermatogenesis tracked over multi-month horizons. trial
- Avoid continuous non-pulsatile high exposure: Continuous receptor occupancy is the classic path to pituitary desensitization and LH/FSH suppression (same biology as depot agonists, different molecule/context). trial
- Hypothalamic amenorrhea pump framing: Multi-week ~q90 min regimens with ~21-day reassessment windows in product literature. trial
Timing
- Vs hCG timing: hCG lasts ~24–36 hours → 2–3×/week culture; gonadorelin’s minutes-scale life is why daily/BID camps argue with 2×/week clinic charts. forum
- Plasma half-life: In the reviewed Lutrepulse monograph, IV or SC gonadorelin had an initial half-life of about 2–10 minutes and a terminal half-life of about 10–40 minutes in healthy and hypogonadotropic humans. Renal impairment can prolong exposure. trial
- Why pulses matter: Minutes-scale clearance is why physiologic therapy uses q~90 min pumps, not “one long depot like TRT cypionate.” trial
- Downstream LH/FSH outlast peptide: Gonadotropin and sex-steroid responses last hours after the parent peptide is gone; day-of “feel” is a poor proxy. trial
- Lab timing: Clinical pump studies often draw ~30 min after a pulse; community mid-cycle panels are usually not strictly pulse-timed; post-AAS challenge case work has used ~2-hour post-bolus draws. trial
- Desensitization biology: Continuous GnRH exposure downregulates GnRH receptors and blunts gonadotrophs after an initial stimulatory phase — pulse pattern is the efficacy lever. trial
- Renal note: Impaired kidney function can prolong half-life and reduce clearance in clinical references. trial
More on what it is
- Why people talk about it: Framed as a physiologic hCG alternative for testicular signaling, fertility talk, and TRT adjuncts when hCG is scarce, restricted, or costly; also classic diagnostic stim tests and specialist pulsatile pumps. forum
- Regulatory / product lens: Factrel-class human products and Lutrepulse/Lutrelef pump products are clinical contexts; US human Factrel was discussed as discontinued for commercial reasons unrelated to safety in secondary sources; US research vials and 503A compounded injectables/troches are a different market than hospital diagnostic vials. forum
- Research lens: Compounded mcg charts and gray-market multi-mg research vials ≠ supervised pump or hospital diagnostic protocols. forum
- What it is: Lab-made 10-amino-acid peptide identical to native hypothalamic GnRH (sequence pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 / Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2). Salts discussed as acetate and hydrochloride. trial
- How it works: Pulsed GnRH → pituitary gonadotrophs release LH and FSH → testes/ovaries respond; continuous high exposure can desensitize GnRH receptors and suppress instead of stimulate. trial
- Evidence split: Strong clinical use for diagnostic single-dose stim tests and pulsatile fertility pumps (CHH, hypothalamic amenorrhea); intermittent clinic TRT-adjunct outcomes are mostly clinic marketing + forums, thinner than hCG’s fertility literature. trial
- Not the same as: Not hCG (LH-mimetic at the gonad), not enclomiphene/clomiphene (SERM at brain estrogen receptors), not kisspeptin (upstream of GnRH neurons), not testosterone, not leuprolide/triptorelin depot agonists used to shut the axis down. trial
Stacks
- TRT + gonadorelin: Core pairing in men’s-clinic marketing for testicular signaling while exogenous T suppresses native GnRH. forum
- vs hCG (main comparison, not a true stack): Replace, alternate, or trial after hCG failure/shortage; not 1:1 dose-equivalent swaps (mcg ≠ IU). Clinics often prefer hCG when fertility/function is primary and gonadorelin when size/cost is primary. forum
- with hCG: Some combine for dual pathway talk (pituitary + direct Leydig); dual stimulation can raise estrogen-management burden and cost. forum
- SERMs (clomiphene / enclomiphene): Often co-mentioned for PCT or to blunt estrogen negative feedback so pituitary output can rise on or after TRT; ExcelMale-style commentary argues gonadorelin alone may be weak under heavy T feedback without a SERM — confounded and debated. forum
- Aromatase inhibitors: Anastrozole-class agents when E2 rises with restored gonadotropins or concurrent hCG/T; some clinic call scripts assume AI co-use is common when chasing high total-T targets. forum
- Kisspeptin-10: Minority “full axis” stacks (kisspeptin → GnRH neurons; gonadorelin = GnRH itself); thin outcome data, overlapping desensitization concerns with non-physiologic continuous exposure. forum
- Not a GHRH stack twin: Forums sometimes list it next to sermorelin/CJC/ipamorelin/tesamorelin because all are “peptides,” but HPG ≠ GH axis — different receptors and goals; co-logging in apps reflects concurrent optimization culture, not synergy proof. forum
- PT-141 / desire stacks: Occasional co-mention or co-compounded nasal talk for libido; effects hard to attribute. anecdote
- GLP-1 / multi-peptide lifestyle stacks: App co-reports with retatrutide, tirzepatide, BPC-157, GHK-Cu, MOTS-c, NAD+ appear as concurrent use culture — not evidence of a designed endocrine synergy. anecdote
- FSH / hMG talk: Clinical fertility regimens may pair LH activity with FSH activity; gonadorelin’s dual LH+FSH release is marketed as a single-peptide partial substitute for that idea in hypogonadotropic contexts. trial
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Weak response on TRT: High T/E2 feedback can blunt pituitary output so intermittent gonadorelin underperforms direct hCG at the testis; clinics openly call response “less predictable” than hCG. forum
- Pituitary non-response: If gonadotrophs are damaged or fully suppressed, upstream GnRH cannot create LH/FSH — hCG may still act at the gonad. forum
- Estrogen swing: Rising endogenous gonadotropins (± concurrent T/hCG) can shift E2 with mood, water, libido, or gynecomastia-adjacent complaints. forum
- Fertility not guaranteed: Even with adjunct therapy, sperm parameters on TRT can stay poor; banking and specialist care are repeatedly emphasized. forum
- Source quality: Research/compounded vials vary in identity, sterility, and labeled potency; clinic product ≠ gray-market powder. forum
- Special populations: Pregnancy, active pituitary disease, and planned fertility need clinical oversight — not solo research-vial improvisation. forum
- Injection site: Redness, itch, pain, swelling, local hardening; chronic SC can show local/generalized rash in labeling-era reports; pump series commonly note skin allergic erythema/scleroma. trial
- Short systemic (Factrel-class): Headache, flushing, nausea, abdominal discomfort, dizziness/lightheadedness after ~100 mcg challenges — usually brief when they occur; labeling described systemic effects as rare after single 100 mcg doses. trial
- Allergy / hypersensitivity: Rash, hives; rare multi-dose hypersensitivity (bronchospasm, tachycardia, urticaria, site induration) and rare anaphylaxis after multiple doses — stop and seek care if systemic allergy signs. trial
- Pituitary tumor caution: Report of pituitary apoplexy and sudden blindness after GnRH administration in a patient with a gonadotropin-secreting adenoma — relevant to diagnostic use with known pituitary masses. trial
- Desensitization paradox: Too frequent, continuous, or chronically high exposure can suppress LH/FSH after an initial rise — opposite of the TRT-adjunct goal. trial
- Primary hypogonadism / bad testes: Broken Leydig/germinal tissue will not be fixed by more GnRH or LH signal — same limitation class as hCG. trial
- Androgen-related effects when T rises: Acne and breast tenderness reported in some pump/hypogonadism restoration contexts as sex steroids climb (sometimes more noted on high-T gonadotropin regimens than on carefully titrated pumps). trial
- Confusion with depot agonists: Continuous long-acting GnRH agonists are used to shut the axis down (prostate, puberty, endometriosis contexts) — same receptor family, opposite pulse strategy. trial
- Veterinary products are not human protocols: Cattle IM gonadorelin products (e.g. Factrel Injection veterinary labeling) are a different regulatory and dose context. trial
Evidence mix
Mixed trial + community tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.